APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dipeptide Peptidase 4 (DPP-4) Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Outlook and Growth Opportunities 2026

20 December 2025194 pages

Choose your research edition.

Industry ResearchDipeptide Peptidase 4 (DPP-4) Inhibitors Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Dipeptide Peptidase 4 (DPP-4) Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Dipeptide Peptidase 4 (DPP-4) Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Dipeptide Peptidase 4 (DPP-4) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Dipeptide Peptidase 4 (DPP-4) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dipeptide Peptidase 4 (DPP-4) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Dipeptide Peptidase 4 (DPP-4) Inhibitors market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Dipeptide Peptidase 4 (DPP-4) Inhibitors market include Takeda Pharmaceutical Company, Merck, Eli Lilly, Boehringer Ingelheim, BMS and AstraZenica, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Dipeptide Peptidase 4 (DPP-4) Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Dipeptide Peptidase 4 (DPP-4) Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Dipeptide Peptidase 4 (DPP-4) Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Dipeptide Peptidase 4 (DPP-4) Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Dipeptide Peptidase 4 (DPP-4) Inhibitors Segment by Company

Takeda Pharmaceutical Company

Merck

Eli Lilly

Boehringer Ingelheim

BMS

AstraZenica

Dipeptide Peptidase 4 (DPP-4) Inhibitors Segment by Type

Alogliptin

Linagliptin

Sitagliptin

Saxagliptin

Vildagliptin

Dipeptide Peptidase 4 (DPP-4) Inhibitors Segment by Application

Hospitals

Clinics

Dipeptide Peptidase 4 (DPP-4) Inhibitors Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Dipeptide Peptidase 4 (DPP-4) Inhibitors status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Dipeptide Peptidase 4 (DPP-4) Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Dipeptide Peptidase 4 (DPP-4) Inhibitors significant trends, drivers, influence factors in global and regions.

6. To analyze Dipeptide Peptidase 4 (DPP-4) Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dipeptide Peptidase 4 (DPP-4) Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dipeptide Peptidase 4 (DPP-4) Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dipeptide Peptidase 4 (DPP-4) Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Dipeptide Peptidase 4 (DPP-4) Inhibitors market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Dipeptide Peptidase 4 (DPP-4) Inhibitors industry.

Chapter 3: Detailed analysis of Dipeptide Peptidase 4 (DPP-4) Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Dipeptide Peptidase 4 (DPP-4) Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Dipeptide Peptidase 4 (DPP-4) Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Trends Table 2. Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Drivers Table 3. Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Opportunities and Challenges Table 4. Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Restraints Table 5. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Share by Company (2021-2026) Table 7. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume Share by Company (2021-2026) Table 9. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Company Ranking, (2024-2026) & (USD Million) Table 11. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Key Company Manufacturing Base & Headquarters Table 12. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Company, Product Type & Application Table 13. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Alogliptin Table 18. Significant Companies of Linagliptin Table 19. Significant Companies of Sitagliptin Table 20. Significant Companies of Saxagliptin Table 21. Significant Companies of Vildagliptin Table 22. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume Share by Type (2021-2026) Table 26. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume Share by Type (2027-2032) Table 27. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type (2021-2026) Table 31. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hospitals Table 33. Significant Companies of Clinics Table 34. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume Share by Application (2021-2026) Table 38. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume Share by Application (2027-2032) Table 39. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application (2021-2026) Table 43. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application (2027-2032) Table 44. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region (2021-2026) & (K Units) Table 46. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Region (2021-2026) Table 47. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region (2027-2032) & (K Units) Table 48. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Region (2027-2032) Table 49. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Region (2021-2026) Table 52. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Region (2027-2032) Table 54. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2021-2026) & (K Units) Table 59. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Country (2021-2026) Table 60. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2027-2032) & (K Units) Table 61. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Country (2027-2032) Table 62. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Market Share by Country (2021-2026) Table 64. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Market Share by Country (2027-2032) Table 66. Takeda Pharmaceutical Company Company Information Table 67. Takeda Pharmaceutical Company Business Overview Table 68. Takeda Pharmaceutical Company Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Takeda Pharmaceutical Company Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio Table 70. Takeda Pharmaceutical Company Recent Development Table 71. Merck Company Information Table 72. Merck Business Overview Table 73. Merck Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Merck Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio Table 75. Merck Recent Development Table 76. Eli Lilly Company Information Table 77. Eli Lilly Business Overview Table 78. Eli Lilly Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Eli Lilly Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio Table 80. Eli Lilly Recent Development Table 81. Boehringer Ingelheim Company Information Table 82. Boehringer Ingelheim Business Overview Table 83. Boehringer Ingelheim Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Boehringer Ingelheim Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio Table 85. Boehringer Ingelheim Recent Development Table 86. BMS Company Information Table 87. BMS Business Overview Table 88. BMS Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. BMS Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio Table 90. BMS Recent Development Table 91. AstraZenica Company Information Table 92. AstraZenica Business Overview Table 93. AstraZenica Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. AstraZenica Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio Table 95. AstraZenica Recent Development Table 96. Key Raw Materials Table 97. Raw Materials Key Suppliers Table 98. Dipeptide Peptidase 4 (DPP-4) Inhibitors Distributors List Table 99. Dipeptide Peptidase 4 (DPP-4) Inhibitors Customers List Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Image Figure 2. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 4. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Alogliptin Image Figure 10. Linagliptin Image Figure 11. Sitagliptin Image Figure 12. Saxagliptin Image Figure 13. Vildagliptin Image Figure 14. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume Share by Type (2021-2032) Figure 17. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type (2021-2032) Figure 20. Hospitals Image Figure 21. Clinics Image Figure 22. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume Share by Application (2021-2032) Figure 25. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application (2021-2032) Figure 28. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 33. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 39. South America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Dipeptide Peptidase 4 (DPP-4) Inhibitors Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Alogliptin
  • Linagliptin
  • Sitagliptin
  • Saxagliptin
  • Vildagliptin
Applications
  • Hospitals
  • Clinics
Companies covered
  • Takeda Pharmaceutical Company
  • Merck
  • Eli Lilly
  • Boehringer Ingelheim
  • BMS
  • AstraZenica

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value (2021-2032)
  4. 1.2.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume (2021-2032)
  5. 1.2.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Dynamics
  1. 2.1 Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Trends
  2. 2.2 Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Drivers
  3. 2.3 Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Opportunities and Challenges
  4. 2.4 Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Restraints
3 Dipeptide Peptidase 4 (DPP-4) Inhibitors Market by Company
  1. 3.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Company Revenue Ranking in 2025
  2. 3.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Company (2021-2026)
  3. 3.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume by Company (2021-2026)
  4. 3.4 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Average Price by Company (2021-2026)
  5. 3.5 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Company Ranking (2024-2026)
  6. 3.6 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Company Manufacturing Base and Headquarters
  7. 3.7 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Company Product Type and Application
  8. 3.8 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Dipeptide Peptidase 4 (DPP-4) Inhibitors Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Dipeptide Peptidase 4 (DPP-4) Inhibitors Market by Type
  1. 4.1 Dipeptide Peptidase 4 (DPP-4) Inhibitors Type Introduction
  2. 4.1.1 Alogliptin
  3. 4.1.2 Linagliptin
  4. 4.1.3 Sitagliptin
  5. 4.1.4 Saxagliptin
  6. 4.1.5 Vildagliptin
  7. 4.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume by Type
  8. 4.2.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Type
  12. 4.3.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Type (2021-2032)
  14. 4.3.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type (2021-2032)
5 Dipeptide Peptidase 4 (DPP-4) Inhibitors Market by Application
  1. 5.1 Dipeptide Peptidase 4 (DPP-4) Inhibitors Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume by Application
  5. 5.2.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Application
  9. 5.3.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Application (2021-2032)
  11. 5.3.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application (2021-2032)
6 Dipeptide Peptidase 4 (DPP-4) Inhibitors Regional Sales and Value Analysis
  1. 6.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region: 2021-2026
  4. 6.2.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region (2027-2032)
  5. 6.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Region (2021-2032)
  7. 6.4.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Region: 2021-2026
  8. 6.4.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Region (2027-2032)
  9. 6.5 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value (2021-2032)
  12. 6.6.2 North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value (2021-2032)
  15. 6.7.2 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value (2021-2032)
  21. 6.9.2 South America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Country, 2025 VS 2032
7 Dipeptide Peptidase 4 (DPP-4) Inhibitors Country-level Sales and Value Analysis
  1. 7.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2021-2032)
  4. 7.3.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2021-2026)
  5. 7.3.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2027-2032)
  6. 7.4 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Country (2021-2032)
  7. 7.4.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Country (2021-2026)
  8. 7.4.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical Company
  2. 8.1.1 Takeda Pharmaceutical Company Company Information
  3. 8.1.2 Takeda Pharmaceutical Company Business Overview
  4. 8.1.3 Takeda Pharmaceutical Company Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Company Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Company Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Eli Lilly
  14. 8.3.1 Eli Lilly Company Information
  15. 8.3.2 Eli Lilly Business Overview
  16. 8.3.3 Eli Lilly Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio
  18. 8.3.5 Eli Lilly Recent Developments
  19. 8.4 Boehringer Ingelheim
  20. 8.4.1 Boehringer Ingelheim Company Information
  21. 8.4.2 Boehringer Ingelheim Business Overview
  22. 8.4.3 Boehringer Ingelheim Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Boehringer Ingelheim Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio
  24. 8.4.5 Boehringer Ingelheim Recent Developments
  25. 8.5 BMS
  26. 8.5.1 BMS Company Information
  27. 8.5.2 BMS Business Overview
  28. 8.5.3 BMS Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 BMS Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio
  30. 8.5.5 BMS Recent Developments
  31. 8.6 AstraZenica
  32. 8.6.1 AstraZenica Company Information
  33. 8.6.2 AstraZenica Business Overview
  34. 8.6.3 AstraZenica Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AstraZenica Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio
  36. 8.6.5 AstraZenica Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Dipeptide Peptidase 4 (DPP-4) Inhibitors Value Chain Analysis
  2. 9.1.1 Dipeptide Peptidase 4 (DPP-4) Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Mode & Process
  6. 9.2 Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Dipeptide Peptidase 4 (DPP-4) Inhibitors Distributors
  9. 9.2.3 Dipeptide Peptidase 4 (DPP-4) Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst